Clinical trial · Interventional
Bronchoscopy Assisted by Electromagnetic Navigation (EMN) in the Diagnosis of Small Pulmonary Nodules
Role of Bronchoscopy Assisted by Electromagnetic Navigation (EMN) in the Diagnosis of Small Pulmonary Nodules of Indeterminate Nature. A Prospective Study by the European Lung Cancer Working Party.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Due to CT screening, a lot of peripheral nodule not accessible to conventional endoscopy will be found. Electromagnetic navigation directed bronchoscopy (ENB) is a new technique needing validation. the primary aim of the study is to compare ENB to radiologically guided bronchoscopy, considered the standard comparator.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pulmonary Nodule Cm | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bronchoscopy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Bronchoscopy guided by fluoroscopy
- description
- Bronchoscopy guided by fluoroscopy followed by ENG
- interventionNames
- Procedure: Bronchoscopy
- type
- EXPERIMENTAL
- label
- Bronchoscopy guided by electromagnetic navigation
- description
- Bronchoscopy guided by ENG followed by fluoroscopy
- interventionNames
- Procedure: Bronchoscopy
Primary outcomes (1)
- measure
- Capability of diagnosing lung nodule with ENB (Sensitivity)
- timeFrame
- After the procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Presence on a conventional or low dose chest CT at least one lung nodule 5-20 mm in its largest axis, of indeterminate nature; the nodule must be positive at PET-CT examination (in case of PET-CT negative, only follow-up is proposed) * The pulmonary nodule(s) must be known for less than 6 months * The nodule appearance can be solid, presents as a ground glass opacity with solid component or as pure ground glass opacity * Availability for participating in the detailed follow-up of the protocol * Signed informed consent. * Age \> 18 years Exclusion Criteria: * Nodules found in the context of an active infection or for whom, the clinical context and/or additional available investigations (serology, microbiological samplings, immune abnormalities) show that cancer diagnosis is unlikely * Nodules found in the context of an active previously documented disease that can be associated with pulmonary nodules (anthracosilicosis, histoplasmosis, tuberculosis, autoimmune or rheumatoid diseases …) * Calcified nodule * Anticoagulation therapy of any type that cannot be suspended for the duration of the investigation * Respiratory failure, recent myocardial infarction (less than 3 months prior to the date of lung nodule screening), uncontrolled angina pectoris, congestive cardiac failure, cardiac arrhythmia, uncontrolled infectious disease or any other physical, biological or psychological factor which may prevent adherence to the study protocol or which may impair the patient's tolerance to the endoscopy and/or the general anaesthesia * Presence of a implanted cardiac device (pace-maker, defibrillator, …) * Pregnant women
References
Publications (0)
Data not yet available